Abstrak 
Association between +874 T>A polymorphism IFNG gene and cervical cancer patients in Bandung
Panigoro R, Maskoen AM, Susanto H, Sahiratmadja E.
Unpad, 2nd Bandung Molecular Medicine Conference International conference on Molecular Oncology: An Update in Clinical Application Insight on Infection Related Oncology October 5-7 2012
Inggris
Unpad, 2nd Bandung Molecular Medicine Conference International conference on Molecular Oncology: An Update in Clinical Application Insight on Infection Related Oncology October 5-7 2012
+874 T>A polymorphism, HPV
Introduction : Many women are infected with human papillomavirus (HPV), however, only a subset of women infected with persistent high-risk types of HPV will ever develop cervical cancer. Interferon gamma (IFN-?) is one of the key regulatory cytokines that influence the HPV clearance. The production and the function of IFN-? may impaired by the defect of the IFNG gene, leading to the cervical malignant progression.This study aimed to examine the association between IFNG +874 T>A polymorphism and cervical cancer.
Methods:In a case-control study design, consecutive untreated women with cervical cancer who showed for the first time in HasanSadikin Hospital Bandung were enrolled (n =98). Their controls were women who came for PAP smear (n = 81), and were not matched in ages and ethnicities. DNA extracted from blood was amplified by amplification refractory mutation system – polymerase chain reaction (ARMS – PCR) to detect IFNG +874 T>A polymorphism.
Results:The distribution of IFNG genotypes TT, TA and AA for women with cervical cancer who met the inclusion criteria (n = 64) and with negative intraepithelial lesion or malignancy (n = 42) were 14.1%, 50.0%, 35.9% and 7.1%, 52.4%, 40.5%, respectively. No significant differences could be observed between both groups (p= 0.64). Stratifying the cervical cancer women into a group of squamous cell carcinoma (n = 54) revealed no statistical different. Conclusions:In this study, IFNG +874 T>A polymorphismseems not to contribute in susceptibility to cervical cancer. Larger participants for genetic study are required to detect true association for this polymorphism. Identification of other variants in IFNG gene signaling and its role in the development of cervical cancer diseases need to be further examined to provide information for the biological marker, useful for the development of diagnostic and therapeutic strategies.